UNC8209 是一种选择性的基于 PROTAC 的 TANK 结合激酶 1 (TBK1) 降解剂,通过招募 cereblon (CRBN) 介导依赖泛素-蛋白酶体通路的 TBK1 降解并降低 AAK1、GAK 和 AURKA 的丰度,从而抑制肿瘤细胞增殖、削弱体内肿瘤生长、抑制集落形成和克隆源性生长、增强肿瘤细胞对 TNFα 或 IFN-γ 的敏感性、调控细胞周期并诱导轻度细胞凋亡 (apoptosis),可用于透明细胞肾细胞癌、非小细胞肺癌、胰腺导管腺癌的研究(粉色:TBK1 配体 (MS-X37724);蓝色:Cereblon 配体 (MS-Q68284);黑色:连接子)。
UNC8209
产品编号: MS-X83849 分子式: C45H58BrN7O12 分子量: 968.89
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

UNC8209 是一种选择性的基于 PROTAC 的 TANK 结合激酶 1 (TBK1) 降解剂,通过招募 cereblon (CRBN) 介导依赖泛素-蛋白酶体通路的 TBK1 降解并降低 AAK1、GAK 和 AURKA 的丰度,从而抑制肿瘤细胞增殖、削弱体内肿瘤生长、抑制集落形成和克隆源性生长、增强肿瘤细胞对 TNFα 或 IFN-γ 的敏感性、调控细胞周期并诱导轻度细胞凋亡 (apoptosis),可用于透明细胞肾细胞癌、非小细胞肺癌、胰腺导管腺癌的研究(粉色:TBK1 配体 (MS-X37724);蓝色:Cereblon 配体 (MS-Q68284);黑色:连接子)。

生物实验数据

生物活性 UNC8209 is a selective PROTAC-based TANK-binding kinase 1 (TBK1) degrader that recruits cereblon (CRBN) to mediate ubiquitin-proteasome pathway-dependent TBK1 degradation and reduce the abundance of AAK1, GAK, and AURKA, thereby inhibiting tumor cell proliferation, attenuating tumor growth in vivo, suppressing colony formation and clonogenic growth, enhancing tumor cell sensitivity to TNFα or IFN-γ, modulating the cell cycle, and inducing mild apoptosis, and it can be used for research on clear cell renal cell carcinoma, non-small cell lung cancer, and pancreatic ductal adenocarcinoma (pink: TBK1 ligand (MS-X37724); blue: Cereblon ligand (MS-Q68284); black: linker).
IC50 & Target

TBK1

 

体外研究
(In Vitro)

UNC8209 (0.01-3 μM;4-48 小时) 可在 UMRC6、A498、769-P、UMRC2 和 786-O 肾透明细胞癌 (ccRCC) 细胞中强效且选择性地降解 TBK1,且在标准浓度下对 IKKε 蛋白水平的影响极小。
UNC8209 (1 μM;4-24 小时) 通过 CRBN 依赖、蛋白酶体依赖的通路介导 UMRC6 和 A498 肾透明细胞癌 (ccRCC) 细胞中 TBK1 的降解。
UNC8209 (1 μM;6 小时) 处理 UMRC2 肾透明细胞癌 (ccRCC) 细胞可选择性下调 TBK1,并继发下调 AAK1、GAK、AURKA 和 FLJ45252,而对常见 TBK1 抑制剂的脱靶激酶无显著影响。
UNC8209 (1 μM;24 小时) 处理 UMRC6 和 A498 肾透明细胞癌 (ccRCC) 细胞会导致 AAK1、GAK 和 AURKA 的水平降低,这是 TBK1 降解的继发性结果。
UNC8209 (0.1-4 μM;7-14 天) 可强效抑制 VHL 缺陷型 ccRCC 细胞 (769-P、A498、UMRC6、UMRC2、RCC4、786-O、Caki-1) 和 TBK1 活化的正常肾上皮 HK-2 细胞的增殖,而在 TBK1 活性较低的 VHL 功能正常型 ACHN 和 HKC 细胞中活性有限。
UNC8209 (1 μM;4-6 周) 可抑制 VHL 缺陷型 ccRCC 细胞 (769-P, A498, UMRC6, UMRC2, 786-O, Caki-1) 在软琼脂中的锚定非依赖性生长,而在 ACHN 和 HKC 细胞中活性有限。
UNC8209 (0.01-4 μM;24 小时) 可强效降解 TBK1 并抑制 TBK1 激活型非小细胞肺癌 A549 细胞和胰腺导管腺癌 PANC1 细胞的增殖。
UNC8209 (1 μM) 可与 TNF-α (50 ng/mL)、IFN-γ (10 ng/mL) 协同抑制 NSCLC A549 细胞和 PDAC PANC1 细胞的增殖。

Western Blot Analysis

Cell Line: UMRC6, A498, 769-P, UMRC2, 786-O (human clear cell renal cell carcinoma cell lines)
Concentration: 0.01 μM; 0.03 μM; 0.1 μM; 0.3 μM; 1 μM; 3 μM
Incubation Time: 24 h
Result: Induced potent, sustained TBK1 degradation with minimal effect on IKKε at standard concentrations.

Western Blot Analysis

Cell Line: UMRC6, A498, 769-P, UMRC2, 786-O (human clear cell renal cell carcinoma cell lines)
Concentration: 0.01 μM; 0.03 μM; 0.1 μM; 0.3 μM; 1 μM; 3 μM
Incubation Time: 4 h, 24 h, 48 h
Result: Detected TBK1 degradation as early as 4 h post-treatment and persisted for up to 48 h in UMRC6 cells.
Achieved a half-maximal degradation concentration (DC50) of 80 nM and maximal degradation (DMax) of 94% after 24 h in A498 cells.
Achieved a DC50 of 23 nM with a DMax of 94% after 24 h in 769-P cells.
Observed a mild "hook effect" at concentrations above 1 μM in A498 and 769-P cells, with reduced degradation at higher doses.

Western Blot Analysis

Cell Line: UMRC6, A498 (human clear cell renal cell carcinoma cell lines)
Concentration: 1 μM; 1 μM plus MG132 (10 μM)
Incubation Time: 8 h; 24 h
Result: Completely blocked UNC8209-induced TBK1 degradation in UMRC6 cells when treated with MG132.
Abrogated TBK1 degradation in A498 cells after genetic depletion of CRBN using CRISPR/Cas9, phenocopying the effect of MG132.

Western Blot Analysis

Cell Line: UMRC6, A498 (human clear cell renal cell carcinoma cell lines)
Concentration: 1 μM
Incubation Time: 24 h
Result: Reduced the abundance of AAK1, GAK, and AURKA proteins in both UMRC6 and A498 cells.

Cell Proliferation Assay

Cell Line: A549, PABC1
Concentration: 0.01 μM; 0.1 μM; 0.5 μM; 1 μM; 2 μM
Incubation Time: 24 h
Result: Degraded TBK1 and inhibited proliferation of TBK1-active NSCLC.

Cell Proliferation Assay

Cell Line: A549 (human non-small cell lung cancer cell line); PANC1 (human pancreatic ductal adenocarcinoma cell line)
Concentration: 1 μM; 1 μM plus 50 ng/mL TNF-α; 1 μM plus 10 ng/mL IFN-γ
Incubation Time: continuous incubation
Result: Produced a synergistic effect when co-treated with TNF-α or IFN-γ, significantly enhancing suppression of tumor cell growth compared to single-agent treatment.
Produced only modest effects when treated with cytokine alone.
体内研究
(In Vivo)

UNC8209 (10-20 mg/kg;腹腔注射;每日给药;两周半) 可抑制 NSG 小鼠皮下 A498 肾透明细胞癌 (ccRCC) 异种移植物的生长,其中每日 10 mg/kg 剂量表现出显著疗效且毒性极低,而每日 20 mg/kg 剂量疗效更强但耐受性下降。
UNC8209 (10-40 mg/kg;腹腔注射;单次给药) 在单次腹腔注射后可分布于 NSG 小鼠的血浆和皮下 UMRC2 肾透明细胞癌异种移植瘤中,且可通过降解 TBK1 实现可检测的靶点结合。

Animal Model: NOD SCID Gamma (NSG) (6-week-old, male to female ratio 2:1, subcutaneous xenograft with A498 cells)
Dosage: 10 mg/kg; 20 mg/kg
Administration: i.p.; daily; two and a half weeks
Result: Significantly suppressed tumor growth compared to vehicle controls, with reduced tumor volume and tumor weight at 10 mg/kg.
Caused no significant mouse body weight loss, no significant differences in liver, kidney, heart, or spleen weights, and no overt tissue damage on histopathological analysis at 10 mg/kg.
Resulted in greater suppression of tumor volume and weight compared to vehicle and the 10 mg/kg group at 20 mg/kg.
Caused mild mouse body weight loss after two weeks of treatment, and prevented mice from surviving to the planned experimental endpoint at 20 mg/kg.
Substantially downregulated TBK1 protein expression in tumors from both treatment groups, with stronger degradation in the 20 mg/kg group.
Induced concurrent degradation of IKKε in the 20 mg/kg group.
Downregulated AAK1, GAK, and AURKA protein levels in tumors from treated mice.
Animal Model: NOD SCID Gamma (NSG) (bearing established UMRC2 xenografts with tumor diameter ~10 mm)
Dosage: 10 mg/kg; 20 mg/kg; 40 mg/kg
Administration: i.p.; single dose
Result: Was detectable in both plasma and tumor tissues across all treatment groups, with dose-dependent increases in compound levels (non-linear, suggesting potential saturation of absorption or tissue distribution).
Reduced TBK1 protein levels in tumors from treated mice, with a more pronounced effect at lower doses.

化学信息

分子量 968.89
分子式 C45H58BrN7O12

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础